181 related articles for article (PubMed ID: 20971741)
61. Inhibition of melanoma growth and metastasis by combination with (-)-epigallocatechin-3-gallate and dacarbazine in mice.
Liu JD; Chen SH; Lin CL; Tsai SH; Liang YC
J Cell Biochem; 2001; 83(4):631-42. PubMed ID: 11746506
[TBL] [Abstract][Full Text] [Related]
62. Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells.
Gupta S; Ahmad N; Nieminen AL; Mukhtar H
Toxicol Appl Pharmacol; 2000 Apr; 164(1):82-90. PubMed ID: 10739747
[TBL] [Abstract][Full Text] [Related]
63. Thymoquinone enhances the anticancer activity of doxorubicin against adult T-cell leukemia in vitro and in vivo through ROS-dependent mechanisms.
Fatfat M; Fakhoury I; Habli Z; Mismar R; Gali-Muhtasib H
Life Sci; 2019 Sep; 232():116628. PubMed ID: 31278946
[TBL] [Abstract][Full Text] [Related]
64. Epigallocatechin-3-Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action.
Harper CE; Patel BB; Wang J; Eltoum IA; Lamartiniere CA
Prostate; 2007 Oct; 67(14):1576-89. PubMed ID: 17705241
[TBL] [Abstract][Full Text] [Related]
65. Pro-oxidative activities and dose-response relationship of (-)-epigallocatechin-3-gallate in the inhibition of lung cancer cell growth: a comparative study in vivo and in vitro.
Li GX; Chen YK; Hou Z; Xiao H; Jin H; Lu G; Lee MJ; Liu B; Guan F; Yang Z; Yu A; Yang CS
Carcinogenesis; 2010 May; 31(5):902-10. PubMed ID: 20159951
[TBL] [Abstract][Full Text] [Related]
66. Differential proteomic analysis reveals that EGCG inhibits HDGF and activates apoptosis to increase the sensitivity of non-small cells lung cancer to chemotherapy.
Flores-Pérez A; Marchat LA; Sánchez LL; Romero-Zamora D; Arechaga-Ocampo E; Ramírez-Torres N; Chávez JD; Carlos-Reyes Á; Astudillo-de la Vega H; Ruiz-García E; González-Pérez A; López-Camarillo C
Proteomics Clin Appl; 2016 Feb; 10(2):172-82. PubMed ID: 26175166
[TBL] [Abstract][Full Text] [Related]
67. Excellent anti-proliferative and pro-apoptotic effects of (-)-epigallocatechin-3-gallate encapsulated in chitosan nanoparticles on human melanoma cell growth both in vitro and in vivo.
Siddiqui IA; Bharali DJ; Nihal M; Adhami VM; Khan N; Chamcheu JC; Khan MI; Shabana S; Mousa SA; Mukhtar H
Nanomedicine; 2014 Nov; 10(8):1619-26. PubMed ID: 24965756
[TBL] [Abstract][Full Text] [Related]
68. Epigallocatechin-3-gallate suppresses the expression of HSP70 and HSP90 and exhibits anti-tumor activity in vitro and in vivo.
Tran PL; Kim SA; Choi HS; Yoon JH; Ahn SG
BMC Cancer; 2010 Jun; 10():276. PubMed ID: 20537126
[TBL] [Abstract][Full Text] [Related]
69. (-)-Epigallocatechin-3-gallate suppresses liver metastasis of human colorectal cancer.
Maruyama T; Murata S; Nakayama K; Sano N; Ogawa K; Nowatari T; Tamura T; Nozaki R; Fukunaga K; Ohkohchi N
Oncol Rep; 2014 Feb; 31(2):625-33. PubMed ID: 24337301
[TBL] [Abstract][Full Text] [Related]
70. Epigallocatechin-3-gallate attenuates head and neck cancer stem cell traits through suppression of Notch pathway.
Lee SH; Nam HJ; Kang HJ; Kwon HW; Lim YC
Eur J Cancer; 2013 Oct; 49(15):3210-8. PubMed ID: 23876835
[TBL] [Abstract][Full Text] [Related]
71. SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis.
Rabbani SA; Valentino ML; Arakelian A; Ali S; Boschelli F
Mol Cancer Ther; 2010 May; 9(5):1147-57. PubMed ID: 20423991
[TBL] [Abstract][Full Text] [Related]
72. Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models.
Buocikova V; Longhin EM; Pilalis E; Mastrokalou C; Miklikova S; Cihova M; Poturnayova A; Mackova K; Babelova A; Trnkova L; El Yamani N; Zheng C; Rios-Mondragon I; Labudova M; Csaderova L; Kuracinova KM; Makovicky P; Kucerova L; Matuskova M; Cimpan MR; Dusinska M; Babal P; Chatziioannou A; Gabelova A; Rundén-Pran E; Smolkova B
Biomed Pharmacother; 2022 Mar; 147():112662. PubMed ID: 35091237
[TBL] [Abstract][Full Text] [Related]
73. Epigallocatechin-3-gallate pretreatment attenuates doxorubicin-induced cardiotoxicity in rats: A mechanistic study.
Saeed NM; El-Naga RN; El-Bakly WM; Abdel-Rahman HM; Salah ElDin RA; El-Demerdash E
Biochem Pharmacol; 2015 Jun; 95(3):145-55. PubMed ID: 25701654
[TBL] [Abstract][Full Text] [Related]
74. Effect of Y6, an epigallocatechin gallate derivative, on reversing doxorubicin drug resistance in human hepatocellular carcinoma cells.
Wen Y; Zhao RQ; Zhang YK; Gupta P; Fu LX; Tang AZ; Liu BM; Chen ZS; Yang DH; Liang G
Oncotarget; 2017 May; 8(18):29760-29770. PubMed ID: 28423656
[TBL] [Abstract][Full Text] [Related]
75. Anti-melanoma effects of vorinostat in combination with polyphenolic antioxidant (-)-epigallocatechin-3-gallate (EGCG).
Nihal M; Roelke CT; Wood GS
Pharm Res; 2010 Jun; 27(6):1103-14. PubMed ID: 20232120
[TBL] [Abstract][Full Text] [Related]
76. Slowing tumorigenic progression in TRAMP mice and prostatic carcinoma cell lines using natural anti-oxidant from spinach, NAO--a comparative study of three anti-oxidants.
Nyska A; Suttie A; Bakshi S; Lomnitski L; Grossman S; Bergman M; Ben-Shaul V; Crocket P; Haseman JK; Moser G; Goldsworthy TL; Maronpot RR
Toxicol Pathol; 2003; 31(1):39-51. PubMed ID: 12597448
[TBL] [Abstract][Full Text] [Related]
77. Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: potential role of p53.
Amin AR; Wang D; Zhang H; Peng S; Shin HJ; Brandes JC; Tighiouart M; Khuri FR; Chen ZG; Shin DM
J Biol Chem; 2010 Nov; 285(45):34557-65. PubMed ID: 20826787
[TBL] [Abstract][Full Text] [Related]
78. (-)-Epigallocatechin-3-gallate Down-regulates Doxorubicin-induced Overexpression of P-glycoprotein Through the Coordinate Inhibition of PI3K/Akt and MEK/ERK Signaling Pathways.
Satonaka H; Ishida K; Takai M; Koide R; Shigemasa R; Ueyama J; Ishikawa T; Hayashi K; Goto H; Wakusawa S
Anticancer Res; 2017 Nov; 37(11):6071-6077. PubMed ID: 29061787
[TBL] [Abstract][Full Text] [Related]
79. Cationic poly-L-lysine dendrimer complexes doxorubicin and delays tumor growth in vitro and in vivo.
Al-Jamal KT; Al-Jamal WT; Wang JT; Rubio N; Buddle J; Gathercole D; Zloh M; Kostarelos K
ACS Nano; 2013 Mar; 7(3):1905-17. PubMed ID: 23527750
[TBL] [Abstract][Full Text] [Related]
80. Epigallocatechin-3-gallate (EGCG) inhibits PC-3 prostate cancer cell proliferation via MEK-independent ERK1/2 activation.
Albrecht DS; Clubbs EA; Ferruzzi M; Bomser JA
Chem Biol Interact; 2008 Jan; 171(1):89-95. PubMed ID: 17931610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
